Mindfulness Meditation and Sleep Disturbances in Hematopoietic Cell Transplant Patients: Inflammatory Mechanisms

Overview

This randomized, controlled study will compare Mindfulness Awareness Practices for Insomnia (MAP-I) to sleep health education (SHE) in subjects receiving autologous hematopoietic cell transplant for multiple myeloma.
SparkCures ID 1891
Enrollment 24 Patients
Tags
  • Randomization
Trial Sponsors
  • Medical College of Wisconsin
NCT Identifier

NCT04271930

CLOSED

This trial has terminated.

Am I Eligible?

The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.

The following criteria is provided for health care professionals.

Inclusion Criteria:

* ≥18 years of age
* ≤ 1 year since initiation of systemic anti-myeloma therapy
* No prior progression or relapse of myeloma prior to HCT
* Patient should be eligible to receive melphalan 200 mg/m2 as conditioning regimen
* Stem cell graft with \> 2.0 x10\^6 cluster of differentiation 34 cells (CD34+)/kg available for transplant
* Karnofsky Performance Score (KPS) ≥70
* Agreeable to random assignment and data collection, including survey completion and blood draws
* Available to attend the outpatient intervention portion.
* Voluntary written consent must be given before performance of any study related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care

Exclusion Criteria:

* Prior autologous HCT
* Outpatient HCT
* Presence of coexistent amyloidosis
* Presence of known Obstructive Sleep Apnea (OSA)

US Trial Locations

Please visit the ClinicalTrials.gov page for historical site information.

View Centers